Peri-implantitis, Comparing Treatments 970 nm Laser and Mucosal Flap Surgery
Primary Purpose
Peri-Implantitis
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Laser treatment
Mucosal flap surgery
Oral hygiene instructions
Sponsored by
About this trial
This is an interventional treatment trial for Peri-Implantitis focused on measuring Peri-implantitis, Laser treatment, Surgical treatment, Randomized controlled trial, Patient reported outcomes, Clinical outcomes, Microbiology, Immunology
Eligibility Criteria
Inclusion Criteria:
Signs of peri-implantitis around one or more dental implants. All criteria below need to be fulfilled for inclusion.
- Presence of pocket probing depth (PPD) > 5 mm
- Bleeding on probing/suppuration (BOP/Pus)
- At least 2 mm loss of bone, visible on radiographs, after initial osseointegration.
- ≥ 18 years old.
- Patient able to understand Swedish.
Exclusion Criteria:
- Antibiotic treatment 6 months prior to baseline.
- Peri-implant treatment 6 months prior to baseline.
- Myocardial infarction 6 months prior to baseline.
- Previous radiation treatment in the affected jaw area.
- Previous i.v. bisphosphonate treatment.
- Moderate or severe impairment of cognitive function (e.g. dementia).
Sites / Locations
- Danakliniken Specialist Dentistry
- Specialist Dentistry Clinic, Karolinska Institutet, Dept. of Dental Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Laser treatment
Mucosal flap surgery
Arm Description
Laser treatment with diode laser 970nm and settings 1.2W in intervals of max 20s, until satisfactory removal of diseased epithelium and granulation tissue.
Conventional mucosal flap surgery of affected dental implant.
Outcomes
Primary Outcome Measures
Mean change in pocket probing depth (PPD)
Pocket probing depth (PPD) will be measured by a 1 mm graded pocket probe from the bottom of the peri-implant pocket to the marginal mucosa and will be registered on 4 surfaces surrounding the implant.
Secondary Outcome Measures
Mean change in plaque index (PI)
Plaque index (PI) will be measured at 4 sites per implant and assessed as per cent of the total amount of measured implant surfaces.
Mean change in bleeding on probing (BOP)
BOP will be registered on 4 surfaces surrounding the implant after probing the peri-implant pocket with a pocket probe, up to 20 s after the provocation with the probe.
Mean change in presence of suppuration
Presence of suppuration will be registered on 4 surfaces surrounding the implant after probing the peri-implant pocket with a pocket probe, up to 20 s after the provocation with the probe.
Mean change in marginal bone level on radiographs
Measured on radiographs for a fixed point on the dental implant to the marginal bone level.
Mean change in inflammatory response in peri-implant crevicular fluid (PICF)
Analysis of inflammatory meditators in PICF will be performed by commercially available ELISAs or multiplex assays at base line and 6 months. The analytes of interest to be tested are mainly inflammatory cytokines, chemokines, growth factors, proteases, and molecules related to bone remodeling such as for IL-1β, MMP 8, TIMP-1, CSF-1, elastase activity, and RANK-L/OPG ratio.
Mean change in inflammatory response in saliva
Analysis of inflammatory meditators in stimulated saliva will be performed by commercially available ELISAs or multiplex assays at base line and 6 months. The analytes of interest to be tested are mainly inflammatory cytokines, chemokines, growth factors, proteases, and molecules related to bone remodeling such as for IL-1β, MMP 8, TIMP-1, CSF-1, elastase activity, and RANK-L/OPG ratio.
Composition of the subgingival microflora
The bacterial composition in the subgingival microflora will be analyzed by quantitative real-time Polymerase Chain Reaction (qPCR).
Mean change in patient reported outcome using the visual analogue scale (VAS) score
Visual analogue scale (VAS) is used to record the patients pain, discomfort and satisfaction with the treatment. The patients mark their response on a 100 mm line, with low values being no feeling of pain, discomfort or satisfaction, and high values meaning maximum pain, discomfort or satisfaction.
Full Information
NCT ID
NCT04249024
First Posted
October 16, 2019
Last Updated
November 16, 2022
Sponsor
Karolinska Institutet
1. Study Identification
Unique Protocol Identification Number
NCT04249024
Brief Title
Peri-implantitis, Comparing Treatments 970 nm Laser and Mucosal Flap Surgery
Official Title
Comparing Treatment of Peri-implantitis With Either 970 nm Laser or Conventional Mucosal Flap Surgery - a Prospective Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
September 25, 2019 (Actual)
Primary Completion Date
June 21, 2022 (Actual)
Study Completion Date
June 21, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A clinical trial comparing laser treatment and conventional mucosal flap surgery for treatment of peri-implantitis. The main aim of the study is to evaluate if treatment of peri-implantitis with 970 nm laser combined with scaling and root planning (SRP) is clinically comparable to conventional mucosal flap surgery in terms of pocket probing depth reduction.
Detailed Description
The present project aims to evaluate a novel method in treating peri-implantitis, with focus on decreasing the patient's suffering as well as disease progression. Peri-implantitis has a direct influence on both physical and psychological wellbeing and have been related to difficulty in chewing due to loss of implants, bad esthetic appearance as well as high costs. Therefore, it is of importance for the individual as well as for the society to thoroughly investigate any new treatment approaches.
The study is a prospective randomized clinical trial comparing laser treatment (test group) and conventional mucosal flap surgery (active control group). Assessment of clinical variables at baseline and after 6 months. Patient reported outcomes at baseline, directly after treatment and after 10 days.
Primary Objective:
To evaluate if treatment of peri-implantitis with 970 nm laser combined with scaling and root planning (SRP) is clinically comparable to conventional mucosal flap surgery in terms of pocket probing depth reduction.
Secondary Objectives:
To evaluate other clinical and radiological variables connected to peri-implantitis and the inflammation surrounding the dental implant.
To evaluate the patient experience of treatment of peri-implantitis.
To evaluate the inflammatory and microbial response after laser treatment
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peri-Implantitis
Keywords
Peri-implantitis, Laser treatment, Surgical treatment, Randomized controlled trial, Patient reported outcomes, Clinical outcomes, Microbiology, Immunology
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Masking for the assessors of microbial, immunological and radiographic analyses.
Allocation
Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Laser treatment
Arm Type
Experimental
Arm Description
Laser treatment with diode laser 970nm and settings 1.2W in intervals of max 20s, until satisfactory removal of diseased epithelium and granulation tissue.
Arm Title
Mucosal flap surgery
Arm Type
Active Comparator
Arm Description
Conventional mucosal flap surgery of affected dental implant.
Intervention Type
Device
Intervention Name(s)
Laser treatment
Intervention Description
The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
Intervention Type
Procedure
Intervention Name(s)
Mucosal flap surgery
Intervention Description
The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
Intervention Type
Behavioral
Intervention Name(s)
Oral hygiene instructions
Intervention Description
Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
Primary Outcome Measure Information:
Title
Mean change in pocket probing depth (PPD)
Description
Pocket probing depth (PPD) will be measured by a 1 mm graded pocket probe from the bottom of the peri-implant pocket to the marginal mucosa and will be registered on 4 surfaces surrounding the implant.
Time Frame
0-6 months
Secondary Outcome Measure Information:
Title
Mean change in plaque index (PI)
Description
Plaque index (PI) will be measured at 4 sites per implant and assessed as per cent of the total amount of measured implant surfaces.
Time Frame
0-6 months
Title
Mean change in bleeding on probing (BOP)
Description
BOP will be registered on 4 surfaces surrounding the implant after probing the peri-implant pocket with a pocket probe, up to 20 s after the provocation with the probe.
Time Frame
0-6 months
Title
Mean change in presence of suppuration
Description
Presence of suppuration will be registered on 4 surfaces surrounding the implant after probing the peri-implant pocket with a pocket probe, up to 20 s after the provocation with the probe.
Time Frame
0-6 months
Title
Mean change in marginal bone level on radiographs
Description
Measured on radiographs for a fixed point on the dental implant to the marginal bone level.
Time Frame
0-6 months
Title
Mean change in inflammatory response in peri-implant crevicular fluid (PICF)
Description
Analysis of inflammatory meditators in PICF will be performed by commercially available ELISAs or multiplex assays at base line and 6 months. The analytes of interest to be tested are mainly inflammatory cytokines, chemokines, growth factors, proteases, and molecules related to bone remodeling such as for IL-1β, MMP 8, TIMP-1, CSF-1, elastase activity, and RANK-L/OPG ratio.
Time Frame
0-6 months
Title
Mean change in inflammatory response in saliva
Description
Analysis of inflammatory meditators in stimulated saliva will be performed by commercially available ELISAs or multiplex assays at base line and 6 months. The analytes of interest to be tested are mainly inflammatory cytokines, chemokines, growth factors, proteases, and molecules related to bone remodeling such as for IL-1β, MMP 8, TIMP-1, CSF-1, elastase activity, and RANK-L/OPG ratio.
Time Frame
0-6 months
Title
Composition of the subgingival microflora
Description
The bacterial composition in the subgingival microflora will be analyzed by quantitative real-time Polymerase Chain Reaction (qPCR).
Time Frame
0-6 months
Title
Mean change in patient reported outcome using the visual analogue scale (VAS) score
Description
Visual analogue scale (VAS) is used to record the patients pain, discomfort and satisfaction with the treatment. The patients mark their response on a 100 mm line, with low values being no feeling of pain, discomfort or satisfaction, and high values meaning maximum pain, discomfort or satisfaction.
Time Frame
Baseline, directly after treatment, 10 days after and 6 months after treatment.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signs of peri-implantitis around one or more dental implants. All criteria below need to be fulfilled for inclusion.
Presence of pocket probing depth (PPD) > 5 mm
Bleeding on probing/suppuration (BOP/Pus)
At least 2 mm loss of bone, visible on radiographs, after initial osseointegration.
≥ 18 years old.
Patient able to understand Swedish.
Exclusion Criteria:
Antibiotic treatment 6 months prior to baseline.
Peri-implant treatment 6 months prior to baseline.
Myocardial infarction 6 months prior to baseline.
Previous radiation treatment in the affected jaw area.
Previous i.v. bisphosphonate treatment.
Moderate or severe impairment of cognitive function (e.g. dementia).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Annsofi Johannsen
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Danakliniken Specialist Dentistry
City
Danderyd
State/Province
Stockholms Län
ZIP/Postal Code
18231
Country
Sweden
Facility Name
Specialist Dentistry Clinic, Karolinska Institutet, Dept. of Dental Medicine
City
Huddinge
State/Province
Stockholms Län
ZIP/Postal Code
14152
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Peri-implantitis, Comparing Treatments 970 nm Laser and Mucosal Flap Surgery
We'll reach out to this number within 24 hrs